Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis.

IF 2.5 Q2 CLINICAL NEUROLOGY
Laura Saucier, Brian C Healy, Shrishti Saxena, Eunnindy Sanon, Tanuja Chitnis
{"title":"Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis.","authors":"Laura Saucier, Brian C Healy, Shrishti Saxena, Eunnindy Sanon, Tanuja Chitnis","doi":"10.1177/20552173241274567","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury, and serum glial fibrillary acidic protein (sGFAP) reflects reactive astrogliosis. In adult multiple sclerosis (MS), sNfL correlates with relapsing disease activity while sGFAP correlates with progressive disease.</p><p><strong>Objectives: </strong>We evaluate sNfL and sGFAP as biomarkers in pediatric-onset MS (POMS) compared to pediatric healthy controls (PHC), and correlations with the disease course.</p><p><strong>Methods: </strong>In this single-center observational cross-sectional study, we extracted data from a longitudinal database and measured NfL and GFAP from bio-banked serum using single-molecule array technology.</p><p><strong>Results: </strong>The analysis included 61 POMS patients and 45 PHC. Controlling for age and BMI, sNfL was 414% higher and sGFAP was 42.3% higher in POMS. Disability (EDSS) is associated with higher sNfL (<i>β</i> = 0.32, <i>p</i> = 0.002) and higher sGFAP (<i>β</i> = 0.11, <i>p</i> = 0.03). sNfL is associated with MRI lesion burden, recent disease activity (<i>β</i> =0.95, <i>p</i> < 0.001), and untreated status (<i>β</i> = 0.5, <i>p</i> = 0.006).</p><p><strong>Conclusion: </strong>sNfL and sGFAP are elevated in POMS compared to PHC. Both biomarkers are associated with clinical disability. Elevated sGFAP may reflect early neurodegeneration in POMS, while sNfL reflects disease activity and DMT response. Elevated sNfL among some clinically and radiographically stable POMS patients suggests ongoing neuroaxonal injury with a potential role for sNfL monitoring disease stability.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20552173241274567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury, and serum glial fibrillary acidic protein (sGFAP) reflects reactive astrogliosis. In adult multiple sclerosis (MS), sNfL correlates with relapsing disease activity while sGFAP correlates with progressive disease.

Objectives: We evaluate sNfL and sGFAP as biomarkers in pediatric-onset MS (POMS) compared to pediatric healthy controls (PHC), and correlations with the disease course.

Methods: In this single-center observational cross-sectional study, we extracted data from a longitudinal database and measured NfL and GFAP from bio-banked serum using single-molecule array technology.

Results: The analysis included 61 POMS patients and 45 PHC. Controlling for age and BMI, sNfL was 414% higher and sGFAP was 42.3% higher in POMS. Disability (EDSS) is associated with higher sNfL (β = 0.32, p = 0.002) and higher sGFAP (β = 0.11, p = 0.03). sNfL is associated with MRI lesion burden, recent disease activity (β =0.95, p < 0.001), and untreated status (β = 0.5, p = 0.006).

Conclusion: sNfL and sGFAP are elevated in POMS compared to PHC. Both biomarkers are associated with clinical disability. Elevated sGFAP may reflect early neurodegeneration in POMS, while sNfL reflects disease activity and DMT response. Elevated sNfL among some clinically and radiographically stable POMS patients suggests ongoing neuroaxonal injury with a potential role for sNfL monitoring disease stability.

胶质纤维酸性蛋白和神经丝轻链作为小儿多发性硬化症的生物标记物。
背景:血清神经丝蛋白轻链(sNfL)是神经轴突损伤的标志物,而血清胶质纤维酸性蛋白(sGFAP)反映了反应性星形胶质细胞增多。在成人多发性硬化症(MS)中,sNfL 与复发性疾病活动相关,而 sGFAP 与进展性疾病相关:我们评估了作为生物标记物的 sNfL 和 sGFAP 在小儿多发性硬化症(POMS)中与小儿健康对照组(PHC)的比较,以及与疾病进程的相关性:在这项单中心观察性横断面研究中,我们从纵向数据库中提取了数据,并使用单分子阵列技术测量了生物库血清中的NfL和GFAP:分析包括61名POMS患者和45名PHC患者。在控制年龄和体重指数的情况下,POMS 患者的 sNfL 高出 414%,sGFAP 高出 42.3%。残疾(EDSS)与较高的sNfL(β = 0.32,p = 0.002)和较高的sGFAP(β = 0.11,p = 0.03)相关。sNfL与MRI病变负荷、近期疾病活动(β = 0.95,p < 0.001)和未治疗状态(β = 0.5,p = 0.006)相关。这两种生物标志物都与临床残疾有关。sGFAP的升高可能反映了POMS的早期神经变性,而sNfL则反映了疾病的活动性和DMT反应。在一些临床和影像学表现稳定的POMS患者中,sNfL的升高表明神经轴突损伤仍在持续,sNfL在监测疾病稳定性方面具有潜在的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
0.00%
发文量
54
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信